Nigeria expands TB detection with digital tools, diagnose

Nigeria has achieved a significant epidemiological milestone, diagnosing over 450,000 tuberculosis cases in 2025—a dramatic increase that reflects both the scale of the disease burden and the transformative impact of digital health infrastructure. For European investors tracking healthcare opportunities across Africa's largest economy, this expansion signals a maturing market for medical technology, diagnostic platforms, and digital health solutions.

The breakthrough stems from Nigeria's strategic deployment of digital case detection systems and advanced diagnostic tools, addressing what public health officials have long identified as the sector's critical vulnerability: case identification. Historically, TB surveillance in Nigeria relied on fragmented reporting systems, paper-based records, and limited laboratory capacity. An estimated 400,000+ Nigerians develop TB annually, yet only a fraction received formal diagnosis or treatment. The 450,000 case figure in 2025 represents a paradigm shift in epidemiological visibility.

This expansion carries profound implications for investors. The Nigerian healthcare technology sector, valued at approximately €800 million in 2024, is accelerating toward digital-first diagnostics. The TB detection expansion demonstrates government willingness to invest in digital infrastructure and partner with private sector technology providers. Companies supplying electronic health information systems, point-of-care diagnostic devices, and AI-powered screening platforms are positioned to capture significant market share as case detection becomes systematized.

The broader context is crucial: Nigeria bears approximately 10% of the global TB burden, yet faces severe diagnostic bottlenecks, treatment gaps, and drug-resistant TB emergence. WHO estimates suggest 60-70% of TB cases in Nigeria remain undiagnosed. The current detection expansion—likely driven by expanded GeneXpert MTB/RIF molecular testing, mobile health clinics, and digital reporting protocols—represents incremental but measurable progress toward universal case finding.

For European medical device manufacturers and health IT firms, several opportunities emerge. First, supply chain contracts for diagnostic reagents and equipment will expand as testing infrastructure scales. Second, software licensing for electronic TB registers and patient tracking systems represents recurring revenue streams. Third, training and capacity-building contracts with Nigerian health institutions present service revenue opportunities. Companies operating in point-of-care diagnostics, laboratory information systems, and telemedicine platforms should monitor procurement tenders from Nigeria's Federal Ministry of Health and state health agencies.

However, investors must navigate critical risks. Nigeria's healthcare infrastructure remains fragmented across federal, state, and private providers, complicating interoperability and data integration. Funding sustainability is uncertain—digital health initiatives historically depend on donor support (World Bank, Global Fund, Gates Foundation) rather than domestic government budgets. Currency volatility affecting naira-denominated revenues, healthcare workforce shortages limiting technology adoption, and regulatory inconsistency also present headwinds.

The TB detection expansion also signals demand for downstream healthcare services: anti-tuberculosis drugs, treatment monitoring systems, and care coordination platforms. European pharmaceutical and biotech firms should consider licensing strategies or local partnerships to capture treatment market growth. Additionally, the COVID-19 pandemic demonstrated African governments' appetite for rapid diagnostic deployment and digital health infrastructure—TB success today may accelerate adoption of integrated respiratory disease platforms tomorrow.